Infl uence of colloid infusion on coagulation during off-pump coronary artery bypass grafting

Indian Journal of Anaesthesia

Volumn 54, Issue 2, 2010, Pages 147-153

  Muralidhar, K ^a   Garg, Rajnish ^a   Mohanty, Sk ^a   Banakal, Sanjay ^a  

^a Multispecialty Hospital Shaw Mazumdar Medical Centre   (India)

Author keywords

Cardiac; Coagulation; Hydroxyethyl starches; Surgery; Volume replacement; Von willebrand factor

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTIHYPERTENSIVE AGENT; DIAZEPAM; FIBRINOGEN; GELATIN; GELOFUSIN; HAESSTERIL; HEPARIN; HETASTARCH; PROTAMINE; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TIME; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL ARTICLE; COLLOID; ELECTIVE SURGERY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; OFF PUMP CORONARY SURGERY; PARTIAL THROMBOPLASTIN TIME; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; THORAX DRAINAGE; THROMBOCYTE COUNT;

EID: 78951469401     PISSN: 00195049     EISSN: None     Source Type: Journal    
DOI: 10.4103/0019-5049.63653     Document Type: Article

References (36)

1. Boldt J. Influence of different colloid solutions on coagulation status in patients undergoing cardiac surgery. Ann Card Anaesth 2002;5:166-171.
2. Warren BB, Durieux ME. Hydroxyethyl starch: Safe or not? Anesth Analg 1997;84:206-212.
3. Gallandat Huet RC, Siemons AW, Baus D, van Rooyen-Butijn WT, Haagenaars JA, van Oeveren W, et al. A novel hydroxyethyl starch for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 2000;47:1207-1215.
4. Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F. Influence of a new Hydroxyethyl starch preparation (HES 130 /0.4) on coagulation in cardiac surgical patients. J Cardiothorac Vasc Anesth 2001;15:316-321.
5. Vogt N, Drück A, Wohlfeld C. Effect and side effect of HES 130/0.4/6% compared to HES 200/0.5/6% as plasma substitute for endoprothetic surgery [abstract]. Anesthesiol Intensivmed Notfallmed Schmerzther 1998;33:S162.
6. Waitzinger J, Bepperling F, Pabst G, Opitz J, Fackelmeyer A, Boldt J. Effect of a new hydroxyethyl starch (HES) specification (6% HES 130/0.4) on blood and plasma volumes after bleeding in 12 healthy male volunteers. Clin Drug Invest 1999;17:119-125.
7. ®) wahrend praoperativer acuter normovolamer Hamodilution. Anaesthesist 2003;52: 896-904.
8. Boldt J. Volume therapy in cardiac surgery: Does the kind of fluid matter? J Cardiothorac Vasc Anes th 1999;13:752-763.
9. Egli GA, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR. Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation. Br J Anaesth 1997;78:684-689.
10. Laxenaire MC, Charpentier C, Feldman L. Anaghylactoid reaction to colloid plasma substitute: incidence, risk factors, mechanisms: a French multi center prospective study. Ann Fr Anesth Reanim 1994;13:301-310.
11. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4) causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001;92:855-862.
12. Gallandat Huet RC, Siemons AW, Baus D, van Rooyen-Butijn WT, Haagenaars JA, van Oeveren W, et al. A novel hydroxyethyl starch (Voluven ®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 2000;47:1207-1215.
13. Kasper SM, Meinert P, Kampe S, Görg C, Geisen C, Mehlhorn U, et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology 2003;99:42-47.
14. R) on measures of coagulation. Br J Anaesth 2002;89:722-728.
15. Tabuchi N, de Haan J, Gallandat Huet RC, Boonstra PW, van Oeveren W. Gelatin use impairs platelet adhesion during cardiac surgery. Thromb Haemost 1995;74:1447-1451.
16. de Jonge E, Levi M, Berends F, van der Ende AE, ten Cate JW, Stoutenbeek C P. Impaired hemostasis by intravenous administration of a gelatin based plasma expander in human subjects. Thromb Haemost 1998;79:286-290.
17. Treib J, Haass A, Pindur G. Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 1997;78:974-983.
18. de Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 2001;29:1261-1267.
19. Kuitunen A, Hynynen M, Salmenperä M, Heinonen J, Vahtera E, Verkkala K, et al. Hydroxyethyl starch as a prime for cardiopulmonary bypass: effects of two different solutions on hemostasis. Acta Anaesthesiol Scand 1993;37:652-658.
20. Blaicher AM, Reiter WJ, Blaicher W, Kettner SC, Felfernig M, Grabner CM, et al. The effects of hydroxyethyl starch on platelet aggregation in vitro. Anesth Analg 1998;86:1318-1321.
21. Franz A, Bräunlich P, Gamsjäger T, Felfernig M, Gustorff B, Kozek-Langenecker SA. The effects of hydroxyethyl starches of varying molecular weights on platelet function. Anesth Analg 2001;92:1402-1407.
22. Huraux C, Ankri AA, Eyraud D, Sevin O, Ménégaux F, Coriat P, et al. Hemostatic changes in patients receiving hydroxyethyl starch: the influence of ABO blood group. Anesth Analg 2001;92:1396-1401.
23. Strauss RG, Pennell BJ, Stump DC. A randomized, blinded trial comparing the hemostatic effects of pentastarch versus hetastarch. Transfusion 2002;42:27-36.
24. Ruttmann TG, James M F, Aronson I. In vivo investigation into the effects of haemodilution with hydroxyethyl starch (200/0.5) and normal saline on coagulation. Br J Anaesth 1998;80:612-616.
25. Jamnicki M, Zollinger A, Seifert B, Popovic D, Pasch T, Spahn DR. Compromised blood coagulation: an in vitro comparison of hydroxyethy starch 130/0.4 and hydroxyethyl starch 200/0.5 using thromboelastography. Anesth Analg 1998;87:989-893.
26. Entholzner EK, Mielke LL, Calatzis AN, Feyh J, Hipp R, Hargasser SR. Coagulation effects of a recently developed hydroxyethyl starch (HES 130/0.4) compared to hydroxyethyl starches with higher molecular weight. Acta Anaesthesiol Scand 2000;44:1116-1121.
27. Innerhofer P, Fries D, Margreiter J, Klingler A, Kühbacher G, Wachter B, et al. The effects of peri operatively administered colloids and crystalloids on primary platelet mediated hemostasis and clot formation. Anesth Analg 2002;95:858-865.
28. Stibbe J, Kirby E P. The influence of Haemaccel, fibrinogen and albumin on ristocetin-induced platelet aggregation. Relevance to the quantitative measurement of the ristocetin cofactor. Thromb Res 1976;8:151-165.
29. Stibbe J, van der Plas PM, Ong GL, ten Hoor F, Nauta J, de Jong DS, et al. Effects of gelatin plasma substitutes, Haemaccel, Plasmagel and Plasmion (Geloplasma) on collagen, ADP and adrenaline induced aggregation of human platelets in vitro. Haemostasis 1971;10:276-288.
30. Haisch G, Boldt J, Krebs C, Suttner S, Lehmann A, Isgro F. Influence of a new hydroxyethylstarch preparation (HES 130/0.4) on coagulation cardiac surgical patients J Cardiothorac Vasc Anesth 2001;15:316-321.
31. London MJ, Franks M, Verrier ED, Merrick SH, Levin J, Mangano DT. The safety and efficacy of ten percent pentastarch as a cardiopulmonary bypass priming solution. J Thorac Cardiovasc Surg 1992;104:284-296.
32. Tigchelaar I, Gallandat Huet RC, Korsten J, Boonstra P W, van Oeveren W. Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypass. Eur J Cardiothorac Surg 1997;11:626-632.
33. Canver CC, Nichols RD. Use of intraoperative hetastarch priming during coronary bypass. Chest 2000;118:1616-1620.
34. Van der Linden PJ, De Hert SG, Daper A, Trenchant A, Schmartz D, Defrance P, et al. 3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients: [La gélatine à pont d'urée à 3,5% est aussi efficace que de l'HEA 200/0,5 à 6% pour le remplissage vasculaire des patients de chirurgie cardiaque]. Can J Anaesth 2004;51:236-241.
35. Van der Linden PJ, De Hert SG, Deraedt D, Cromheecke S, De Decker K, De Paep R, et al. Hydroxyethyl Starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth Analg 2005;101:629-634. 36.
36. Lang K, Suttner S, Boldt J, Kumle B, Nagel D. Volume replacement with HES 130/0.4 may reduce the inflammatory response in patients undergoing major abdominal surgery [Le remplissage vasculaire avec de l'HEA 130/0,4 peut réduire la réaction inflammatoire chez des patients en chirurgie abdominale majeure]. Can J Anesth 2003;50:1009-1016.